- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01891357
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer
Study Overview
Status
Conditions
Detailed Description
Trastuzumab (T)-containing neoadjuvant chemotherapy has been reported to increase the probability of pathological complete response (pCR) in HER2 positive disease up to 67 %. Large trials revealed pCR rates (no remaining invasive and in situ components) of about 30-40 %, if anthracyclines/taxane based polychemotherapy was applied or about 40-45 % if no invasive tumor in the breast and lymph nodes was used as a pCR definition.
Nevertheless, resistance to trastuzumab remains one of the most important challenges in adjuvant and metastatic breast cancer therapy causing poor prognosis with an increased incidence of cerebral metastasis and limited therapeutic options after disease progression6. An improvement shows the combination of trastuzumab and lapatinib, which has been reported to have increased efficacy in in-vitro and in metastatic setting in patients who were mostly resistant to both therapies in the previous course of disease. Recent data from the neoadjuvant setting (neoALTTO) - on a paclitaxel backbone - showed a significantly higher pCR rate after L + T than with either compound separately (47 % vs. 20 % and 27.6 % respectively). Several trials are planned to evaluate the combination of both therapies in the adjuvant and neoadjuvant setting.
Clinical response measured by sequential evaluation of different proliferation markers (such as Ki-67) following a course of neoadjuvant chemotherapy has been demonstrated to correlate significantly with an increased risk of relapse in patients not achieving pathological complete response. It is therefore clinically relevant to evaluate such proliferation tools for early prediction of combination therapy efficacy (chemotherapy and HER2 targeted therapy). So far, it remains unclear which method of proliferation measurement is the optimal marker for response evaluation regarding a combined chemo-immunotherapy. However, measurement of proliferation and apoptosis genes as well as assessment of changes in Phosphatidylinositol 3-kinases (PI3K), Protein Kinase B (AKT), Insulin-like Growth Factor (IGF) and stem cell signalling after a short course of therapy could provide a unique signature for a dynamic response evaluation.
The planned trial will validate predictive markers and a dynamic model based on the sequential evaluation of different proliferation and apoptosis markers. Furthermore it will assess the pCR-rate after 12 weeks of therapy. The aim of the study is to define a predictive marker for the response evaluation of a combined chemo-immunotherapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10713
- Praxis für gynäkologische Onkologie am Brustzentrum City
-
-
Baden-Württemberg
-
Esslingen, Baden-Württemberg, Germany, 73730
- Klinikum Esslingen
-
Heilbronn, Baden-Württemberg, Germany, 74078
- SLK Kliniken
-
-
Hessen
-
Frankfurt (Main), Hessen, Germany, 65929
- Klinikum Frankfurt Höchst
-
-
Niedersachsen
-
Georgsmarienhütte, Niedersachsen, Germany, 49124
- Niels-Stensen-Kliniken
-
-
Nordrhein-Westfalen
-
Dortmund, Nordrhein-Westfalen, Germany, 44309
- Klinikum Westfalen GmbH - Knappschaftskrankenhaus
-
Duisburg, Nordrhein-Westfalen, Germany, 47053
- Bethesda Krankenhaus, Senologie
-
Hamm, Nordrhein-Westfalen, Germany, 59073
- St. Barbara-KIinik
-
Köln, Nordrhein-Westfalen, Germany, 51067
- Krankenhaus Köln Holweide, Brustzentrum
-
-
Sachsen
-
Chemnitz, Sachsen, Germany, 09116
- Klinikum Chemnitz gGmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients, age at diagnosis 18 - 75 years
- Histological confirmed unilateral primary invasive carcinoma of the breast
- Clinical Stage Tumor 1 (cT1) (> 1 cm) - Clinical Stage Tumor 4 (cT4) (if operable, inflammatory breast cancer is excluded)
- HER2 over-expressing tumor confirmed by: 3+ by Immuno-histochemistry (IHC) and/or HER2/neu gene amplification by fluorescence, chromogenic or silver in-situ hybridization [Fluorescent In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH) or Silver In-Situ Hybridization (SISH); > 6 HER2 gene copies per nucleus or a FISH, CISH or SISH test ratio (HER2 gene copies to chromosome 17 signals) of ≥ 2.0]
- Clinically node positive disease or node negative disease
- No clinical evidence for distant metastasis (cM0) after conventional staging
- Performance Status Eastern Cooperative Oncology Group (ECOG) ≤ 1 or Karnofsky Index (KI) ≥ 80%
- Baseline Left Ventricular Ejection Fraction (LVEF) > 50% measured by echocardiography
- Negative pregnancy test (urine or serum) within 7 days prior to start of induction treatment in premenopausal patients
- The patient must be accessible for treatment and follow-up
- Written informed consent including a written informed consent for shipping of tumor block for central pathology review and evaluation prior to the start of any study procedures
Exclusion Criteria:
- Known hypersensitivity reaction to the compounds or incorporated substances
- Known polyneuropathy grade ≥ 2
- Have acute or currently active or requiring anti-viral therapy hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, stable chronic liver disease per investigator assessment).
- Prior malignancy with a disease-free survival of < 10 years, except curatively treated basalioma of the skin, pTis of the cervix uteri
- Prior or concurrent treatment with cytotoxic agents for any reason after consultation with the sponsor
- Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry
- Male breast cancer
- Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment
- Breast feeding women
- Sequential breast cancer
- Lack of patient compliance
Inadequate organ function including:
- Leucocytes < 3.5 x 109/l
- Platelets < 100 x 109/l
- Absolute Neutrophil Count (ANC) < 1.5 x 109/l
- Hemoglobin < 9 g/dl
- Serum Creatinine > 1.5 mg/dl
- Serum Bilirubin > 1.1 mg/dl
- Alkaline phosphatase > 2.5 x Upper Limit of Normal (ULN)
- Aspartate Transaminase (ASAT) and/or Alanine Transaminase (ALAT) > 2.5 ULN
- Albumin < 2.5 g/dl
- Uncompensated cardiac function
- Malabsorption syndrome, disease significantly affecting gastrointestinal function
- Concomitant use of Cytochrome P450 3A4 (CYP3A4) inhibitors or inducers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Paclitaxel + Lapatinib + Trastuzumab
Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O.
daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment
|
Core biopsies for histological analyses, to be analysed by the central pathology
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Complete Response (pCR)
Time Frame: Average of 16 weeks
|
pCR was defined at the time of surgery and measured by size of residual tumor, proportion of vital cells within invasive carcinoma, number of positive lymph nodes (ypN) and size of the largest lymph node metastasis and ductal carcinoma in situ (ypT).
pCR is defined as ypT0/is, ypN0.
Further exploratory pCR definitions were ypT0, ypN0 (total pCR) and ypT0/is (near pCR).
|
Average of 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Event Free Survival (EFS)
Time Frame: 5-year survival
|
5-year survival
|
Overall Survival (OS)
Time Frame: 5-year survival
|
5-year survival
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proliferation and Apoptosis Genes
Time Frame: One week before and after three weeks of treatment
|
Proliferation Ki-67, Aurora A Kinase (STK15), survivin, Myb-related protein B (MYBL2),Cyclin B1 and apoptosis genes Bcl2, Epidermal Growth Factor-like 2 (SCUBE2), cleaved caspase C3 will be assessed in the samples from diagnostic and sequential biopsy.
|
One week before and after three weeks of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mathias Warm, MD, Krankenhaus Köln Holweide
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Breast Neoplasms
- Neoplasms, Ductal, Lobular, and Medullary
- Carcinoma, Ductal
- Carcinoma, Ductal, Breast
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Paclitaxel
- Trastuzumab
- Lapatinib
Other Study ID Numbers
- WSG-AM07 (Neo-PREDICT-HER2)
- 2012-003679-21 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Ductal, Breast
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast... and other conditionsUnited States
-
Roswell Park Cancer InstituteNot yet recruitingBreast Carcinoma | Breast Ductal Carcinoma in Situ
-
Stanford UniversityRecruitingSurgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (NORDIS)Ductal Breast Carcinoma in SituUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyCompletedInflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast Carcinoma | Tubular Ductal Breast CarcinomaUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteAmgenActive, not recruitingBreast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal CarcinomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Pfizer; University of California, San Francisco and other collaboratorsRecruitingPostmenopausal | Ductal Breast Carcinoma In SituUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupActive, not recruitingDuctal Breast Carcinoma In SituUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingBreast Ductal Carcinoma In SituUnited States, Canada, Puerto Rico, Korea, Republic of
-
University of ChicagoNational Cancer Institute (NCI)WithdrawnStage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | Invasive Ductal Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In SituUnited States
Clinical Trials on paclitaxel
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
Shengjing HospitalRecruiting
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
CTI BioPharmaTerminatedNSCLCUnited States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
CTI BioPharmaTerminated
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium